Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation (Resistance)
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV-1, treatment experienced
Eligibility Criteria
Inclusion Criteria: Clinically stable HIV-1 infected participants Ages >18 and <65 years Documented M184V mutation CD4 cell count >100 cells/mL Plasma HIV-1 RNA levels >5000 and <150,000 copies/milliliter (mL) Currently receiving lamivudine or emtricitabine Other hematologic and metabolic parameters must be met. Provide written informed consent Other inclusion criteria apply. Exclusion Criteria: Hepatitis B antigen positive HIV-1 genotype positive for more than or equal to 4 protease mutations HIV-1 genotype positive for more than or equal to 2 non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations Previous therapy with cytotoxic or myelosuppressive drugs in the past 3 months Evidence or history of cirrhosis Women who are pregnant or breast feeding Other exclusion criteria apply.
Sites / Locations
- Clinical Trial Site
- Clinical Trial Site
- Clinical Trial Site
- Clinical Trial Site
- Clinical Trial Site
- Clinical Trial Site
- Clinical Trial Site
- Clinical Trial Site
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
A
B